Novo Nordisk's (NYSE: NVO) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt ...

A Prime Therapeutics analysis of real-world data has found that medical costs for patients taking GLP-1 drugs for obesity had increased by about $1,338 per member, compared with a matched control ...

Makers of the popular obesity treatments Wegovy and Zepbound are cutting prices for ... said Wednesday that it will drop prices 23% for all doses of Wegovy. The new monthly price of $499, down ...

WE’VE heard celebrities talk about the positives of Ozempic and other fat loss jabs – but there’s also a host of nasty side ...

In doing so, he left his equalweight (i.e., hold) recommendation intact ... for Wegovy are trailing those of its great rival, Zepbound, from American pharmaceutical titan Eli Lilly (NYSE: LLY).

STOCKHOLM, SE / ACCESS Newswire / April 2, 2025 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (publ) (FN STO:ALZCUR), a pharmaceutical company that develops candidate drugs for diseases ...

In doing so, he left his equalweight (i.e., hold) recommendation intact. His calculations indicate that Zepbound is taking ... prescriptions for starting doses is starker, with the percentages ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Cut to now, when both Wegovy and Zepbound have been removed from the shortage ... namely the creation of a custom form of a drug on a per-patient basis (e.g., when someone needs a formulation or dose ...